FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialResearch in context

FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialResearch in context

Summary: Background: Currently, assessment of candidate pharmacotherapies in patients with non-alcoholic steatohepatitis (NASH) involves invasive liver biopsy. Non-invasive scores, such as the FibroScan-aspartate aminotransferase (FAST) score, are used to identify candidates for therapy, but their...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Vincent Wai-Sun Wong, Quentin M. Anstee, Louise M. Nitze, Anja Geerts, Jacob George, Victor Nolasco, Mette S. Kjær, Steen Ladelund, Philip N. Newsome, Vlad Ratziu
التنسيق: مقال
اللغة:English
منشور في: Elsevier 2023-12-01
سلاسل:EClinicalMedicine
الموضوعات:
Biomarkers
Clinical trial
Non-alcoholic steatohepatitis
NASH
Semaglutide
الوصول للمادة أونلاين:http://www.sciencedirect.com/science/article/pii/S258953702300487X

الانترنت

http://www.sciencedirect.com/science/article/pii/S258953702300487X

مواد مشابهة